tbuckley/cabot-search huggingface dataset:
Population genomics studies identify signatures of global dispersal and drug resistance in Plasmodium vivax
Authors: Daniel N Hupalo, Zunping Luo, Alexandre Melnikov, Patrick L Sutton, Peter Rogov, Ananias Escalante, Andrés F Vallejo, Sócrates Herrera, Myriam Arévalo-Herrera, Qi Fan, Ying Wang, Liwang Cui, Carmen M Lucas, Salomon Durand, Juan F Sanchez, G Christian Baldeviano, Andres G Lescano, Moses Laman, Celine Barnadas, Alyssa Barry, Ivo Mueller, James W Kazura, Alex Eapen, Deena Kanagaraj, Neena Valecha, Marcelo U Ferreira, Wanlapa Roobsoong, Wang Nguitragool, Jetsumon Sattabonkot, Dionicia Gamboa, Margaret Kosek, Joseph M Vinetz, Lilia González-Cerón, Bruce W Birren, Daniel E Neafsey, Jane M Carlton
Journal: Nature Genetics (2016)
RIPK1 and RIPK3 Kinases Promote Cell-Death-Independent Inflammation by Toll-like Receptor 4
Authors: Malek Najjar, Danish Saleh, Matija Zelic, Shoko Nogusa, Saumil Shah, Albert Tai, Joshua N. Finger, Apostolos Polykratis, Peter J. Gough, John Bertin, Michael J. Whalen, Manolis Pasparakis, Siddharth Balachandran, Michelle Kelliher, Alexander Poltorak, Alexei Degterev
Journal: Immunity (2016)
Case 24-1980
Authors: Richard C. Cabot, Robert E. Scully, James J. Galdabini, Betty U. McNeely, Marshall M. Kaplan, James J. Galdabini
Journal: New England Journal of Medicine (1980)

Presentation of CaseA 25-month-old boy was admitted to the hospital because of liver disease.He was born of a second full-term pregnancy that was complicated only by maternal fever at the time of delivery. The birth weight was 3.13 kg. He appeared well at first, but progressive jaundice developed on the seventh day of life and persisted to the age of three months. The conjugated bilirubin rose to a maximum of 4.6 mg per 100 ml (78.66 μper liter), and the total bilirubin to 9.8 mg per 100 ml (167.58 μmol per liter); the serum aspartate aminotransferase (SGOT) rose . . .
bmjlearning.com: Class war
Authors: Kieran Walsh
Journal: BMJ (2006)

“We can formulate the genetic law of cultural development in the following way: any function in the child's cultural development appears on stage twice, on two planes. First it appears on the social plane, then on the psychological, first among people as an interpsychical category and then within the child as an intrapsychical category.” So claimed Lev Vygotsky, a Soviet constructivist psychologist in the first half of the last century.1 Quite what he meant I couldn't say, but I do know that Vygotsky's name has become fashionable among educators, and not least medical educators. Many of his ideas have been enthusiastically applied to medical educational theory.

Educational theory is no doubt a good thing, but can you get too much of it? Are we in danger of missing the wood for the trees? Many traditionalists would argue that we are. We may be educating doctors in a sound format, but are they learning important content? A worrying study by Griffiths and Roberts showed that 45% of junior doctors don't know how to put in a chest drain in a patient with a pneumothorax and, if asked to do one, would insert the drain outside the “triangle of safety” recommended by the British Thoracic Society.2 The triangle of safety is bordered by the anterior border of the latissimus dorsi, the lateral border of the pectoralis major muscle, a line superior to the horizontal level of the nipple, and an apex below the axilla. This is an important piece of information—inserting a drain outside this triangle could do some serious damage.

In his book Class War, the former chief inspector of schools Chris Woodhead says that we have got lost in a maze of pedagogy, and, as a result, our children are failing to learn important pieces of information. He berates academics who claim that being able “to critically analyse work” is more important than learning content (and also bemoans their inability to spot a split infinitive). Could medical education become lost in a similar sea of pedagogy?

At BMJ Learning, we concentrate on content rather than theory—one of our most recent modules is on chest x ray interpretation. It enables you to train and test your skills in diagnosing pleural effusions and pneumothoraces. You might also learn the right place to put in a chest drain, rather than a Bermuda triangle of your own choosing.
A phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX.
Authors: Robert R. McWilliams, Andrew H. Ko, E. Gabriela Chiorean, Eunice Lee Kwak, Heinz-Josef Lenz, Paul I. Nadler, Debra L Wood, Masamoto Fujimori, Kohei Morita, Tetsuhi Inada, Hiroyuki Kouji
Journal: Journal of Clinical Oncology (2015)

e15270 Background: PRI-724 is a first-in-class cAMP-response element-binding protein (CBP)/β-catenin modulator that induces stem cell differentiation. In pre-clinical models, PRI-724 increases p300/β-catenin binding and promotes differentiation, eliminating tumor initiating cells and increasing sensitivity to cytotoxic drugs. Methods: Patients with APC who progressed following first-line therapy with FFX or FX were enrolled. A 3+3 dose escalation design was applied, with GEM (1000 mg/m2 of d1,8,15, 28 d cycle), and PRI-724 administered as a continuous infusion X 7 d every other week. The starting dose was decided at 320 mg/m2/d based on a prior Phase 1a PRI-724 monotherapy study. DLT is defined based on study treatment related AEs. PK and PD sampling for potential biomarkers of PRI-724 activity was performed. Results: The dose-escalation phase was completed with 10 patients in 3 cohorts (320, 640 and 905 mg/m2). Median age was 61 yrs(range 51-70). Nine of 10 pts (90 %) were evaluable for tolerability; 1 pt discontinued early for PD without DLT. Evaluable patients completed a median of 3 cycles (range 1 to 7). The maximum dose was determined to be 905 mg/m2/day, consistent with the Phase 1a study, with no observed DLTs and no MTD established. Of 153 reported AEs with 9 evaluable pts, five gr 3/4 AEs (1 abd pain, 3 neutropenia, and 1alk phos elev) were judged possibly related to study treatment. No related fatal events observed. Median PFS was 2.7 mo. [range 0.97 to 7.2]. Four had a decrease in CA19-9 at the end of Cycle2, with a median decrease of 43% [range 21-76%].Best response by RECIST: 6 SD (including 2 minor responses), 3 PD. Assessments of candidate biomarkers (MMP7 and Claudin 18) are ongoing. Conclusions: In this phase Ib study,PRI-724 administered in combination with GEM demonstrates acceptable toxicity in patients with APC after progression on FFX or FX, with some evidence of clinical activity. Biomarker studies in progress. This dose escalation study determined 905mg/m2/d was generally well tolerated with no MTD reached. A dose expansion cohort of additional 9 patients is enrolling. Clinical trial information: NCT01764477.
Glycoprotein IIb/Iiia Antagonist Could Reduce the Inflammatory Factors IL-6, IL-1β, TNF-α of Atherosclerosis Rabbits in Vivo
Authors: Songmei Yin, Shuangfeng Xie, Yiqing Li, Danian Nie, Liping Ma, Xiuju Wang, Jie Xiao
Journal: Blood (2008)
Lost Colony: Laboratory of Experimental Oncology, San Francisco, 1947–54: Historical Note2
Authors: Michael B. Shimkin
Journal: JNCI Journal of the National Cancer Institute (1978)

Journal Article Lost Colony: Laboratory of Experimental Oncology, San Francisco, 1947–54: Historical Note Get access Michael B. Shimkin Michael B. Shimkin Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 60, Issue 2, February 1978, Pages 479–488, https://doi.org/10.1093/jnci/60.2.479 Published: 01 February 1978 Article history Received: 30 June 1977 Accepted: 08 September 1977 Published: 01 February 1978
A Common Cause of Cranial Nerve VI Palsy—Hidden in Plain Sight
Authors: Anubha Agarwal, Adva Eisenberg, Suzanne K. Woods
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Endpiece: Discredit into which physic was brought
Authors: Jeremy Hugh Baron
Journal: BMJ (2005)

The emperor Adrian ordered it to be inscribed on his tomb, that he died by the hands of his physicians. My son Marcellus, says Cato, if physicians are brought from Greece to Rome, advise the fathers of the Senate that they suffer them not to read or teach physic, or to practise it in the Common Wealth; because the art is too dangerous and difficult, that though it is professed by many it is understood by few.

Miller J. Observations on the management of the prevailing diseases of Great Britain, 1779
Mapping the Interaction of Peptide RPPGF with the Exodomain on Human Protease Activated Receptor 4 (PAR4).
Authors: Marvin T. Nieman, Eileen Pagan-Ramos, Mark Warnock, Yelena Krijanovski, Ahmed A.K. Hasan, Alvin H. Schmaier
Journal: Blood (2004)
Allogenic Transplantation in Lymphomas: A Focused Analysis On Aggressive Lymphomas and Factors Predictive of Outcome in a Series of 179 Pts Treated At John Theurer Cancer Center.
Authors: Anthony R Mato, Kathryn Waksmundzki, Tania Zielonka, Ewelina A Protomastro, Theresa Amatucci, Maria Rosario, Stuart L. Goldberg, Tatyana Feldman, Scott D Rowley, Michele L. Donato, Mary Timberg, Melissa F Baker, Pam Sutherland, Phyllis McKiernan, Andrew L Pecora, Andre Goy
Journal: Blood (2012)
Somatostatin Receptors in an Anaplastic Oligodendroglioma Relapse Evidenced By 68Ga DOTANOC PET/CT
Authors: Giordano Savelli, Alfredo Muni
Journal: Clinical Nuclear Medicine (2015)

Six years ago, a right frontal lobe anaplastic oligodendroglioma negative for AE1/AE3 and HBM-45, positive for 1p/19q deletion, EMA, GFAP, and synaptophysin was excised from a 50-year-old woman. Treatments that followed were radiation therapy, and surgery plus radiation therapy and temozolomide for a relapse with an early partial response, followed by disease progression. In the middle of last year, 68Ga-DOTANOC PET/CT was carried out to evaluate the possibility of treatment with peptide receptor radionuclide therapy. The examination revealed a grossly round-shaped uptake corresponding to the surgical wall, with some smaller uptakes disseminated in different parts of the brain.
Colony-Stimulating Factor-1 Receptor Is Required for Nurse-like Cell Survival in Chronic Lymphocytic Leukemia
Authors: Avery Polk, Ye Lu, Tianjiao Wang, Erlene Seymour, Nathanael G. Bailey, Jack W. Singer, Philip S. Boonstra, Megan S. Lim, Sami Malek, Ryan A. Wilcox
Journal: Clinical Cancer Research (2016)

Monocytes and their progeny are abundant constituents of the tumor microenvironment in lymphoproliferative disorders, including chronic lymphocytic leukemia (CLL). Monocyte-derived cells, including nurse-like cells (NLC) in CLL, promote lymphocyte proliferation and survival, confer resistance to chemotherapy, and are associated with more rapid disease progression. Colony-stimulating factor-1 receptor (CSF-1R) regulates the homeostatic survival of tissue-resident macrophages. Therefore, we sought to determine whether CSF-1R is similarly required for NLC survival.CSF-1R expression by NLC was examined by flow cytometry and IHC. CSF-1R blocking studies were performed using an antagonistic mAb to examine its role in NLC generation and in CLL survival. A rational search strategy was performed to identify a novel tyrosine kinase inhibitor (TKI) targeting CSF-1R. The influence of TKI-mediated CSF-1R inhibition on NLC and CLL viability was examined.We demonstrated that the generation and survival of NLC in CLL is dependent upon CSF-1R signaling. CSF-1R blockade is associated with significant depletion of NLC and consequently inhibits CLL B-cell survival. We found that the JAK2/FLT3 inhibitor pacritinib suppresses CSF-1R signaling, thereby preventing the generation and survival of NLC and impairs CLL B-cell viability.CSF-1R is a novel therapeutic target that may be exploited in lymphoproliferative disorders, like CLL, that are dependent upon lymphoma-associated macrophages. Clin Cancer Res; 22(24); 6118-28. ©2016 AACR.
THE BIOSYNTHESIS OF HEMOGLOBIN
Authors: E J Benz, B G Forget
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Bone Marrow Transplantation: Current Perspectives and Future Directions
Authors: B D Cheson, G A Curt
Journal: JNCI Journal of the National Cancer Institute (1986)

Bone Marrow Transplantation: Current Perspectives and Future Directions Get access Bruce D. Cheson, Bruce D. Cheson 2 2Address reprint requests to Dr. Cheson at the Landow Building, Room 4A18, Bethesda, MD 20892. Search for other works by this author on: Oxford Academic PubMed Google Scholar Gregory A. Curt Gregory A. Curt Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 76, Issue 6, June 1986, Pages 1265–1267, https://doi.org/10.1093/jnci/76.6.1265 Published: 01 June 1986
A Phase 1 Clinical-Pharmacodynamic Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with the Proteasome Inhibitor Bortezomib in Advanced Acute Leukemias.
Authors: Jeffrey E. Lancet, Elliott F. Winton, Robert K. Stuart, Michelle Burton, Christopher Cubitt, Michelle Blaskovich, John Wright, Said Sebti, Daniel Sullivan
Journal: Blood (2008)
Case 21-1979
Authors: Richard C. Cabot, Robert E. Scully, James J. Galdabini, Betty U. McNeely, Edwin O. Wheeler, John T. Fallon
Journal: New England Journal of Medicine (1979)

Presentation of CaseA 17-year-old boy was admitted to the hospital because of a heart murmur.He was born the sixth of nine children, of a normal delivery. His early growth and development were normal. At the age of five years a routine examination at this hospital disclosed no abnormality; the blood pressure was 100/75 mm Hg. At 13 years of age he returned because of diarrhea. Examination revealed marked obesity. The heart was not enlarged; a Grade 3 systolic murmur was heard at the upper sternal border, with radiation over the entire precordium.During the year before entry the . . .
The angiotensin II type 2 receptor activates flow-mediated outward remodelling through T cells-dependent interleukin-17 production
Authors: Antoine Caillon, Céline Grenier, Linda Grimaud, Emilie Vessieres, Anne-Laure Guihot, Simon Blanchard, Eric Lelievre, Marie Chabbert, Etienne D. Foucher, Pascale Jeannin, Céline Beauvillain, Pierre Abraham, Laurent Loufrani, Yves Delneste, Daniel Henrion
Journal: Cardiovascular Research (2016)

The angiotensin II type 1 receptor (AT1R) through the activation of immune cells plays a key role in arterial inward remodelling and reduced blood flow in cardiovascular disorders. On the other side, flow (shear stress)-mediated outward remodelling (FMR), involved in collateral arteries growth in ischaemic diseases, allows revascularization. We hypothesized that the type 2 receptor (AT2R), described as opposing the effects of AT1R, could be involved in FMR. We studied FMR using a model of ligation of feed arteries supplying collateral pathways in the mouse mesenteric arterial bed in vivo. Seven days after ligation, diameter increased by 30% in high flow (HF) arteries compared with normal flow vessels. FMR was absent in mice lacking AT2R. At Day 2, T lymphocytes expressing AT2R were present preferentially around HF arteries. FMR did not occur in athymic (nude) mice lacking T cells and in mice treated with anti-CD3ε antibodies. AT2R activation induced interleukin-17 production by memory T cells. Treatment of nude mice or AT2R-deficient mice with interleukin-17 restored diameter enlargement in HF arteries. Interleukin-17 increased NO-dependent relaxation and matrix metalloproteinases activity, both important in FMR. Remodelling of feeding arteries in the skin flap model of ischaemia was also absent in AT2R-deficient mice and in anti-interleukin-17-treated mice. Finally, remodelling, absent in 12-month-old mice, was restored by a treatment with the AT2R non-peptidic agonist C21. AT2R-dependent interleukin-17 production by T lymphocyte is necessary for collateral artery growth and could represent a new therapeutic target in ischaemic disorders.
Esophageal and transpulmonary pressure in the clinical setting: meaning, usefulness and perspectives
Authors: Tommaso Mauri, Takeshi Yoshida, Giacomo Bellani, Ewan C Goligher, Guillaume Carteaux, Nuttapol Rittayamai, Francesco Mojoli, Davide Chiumello, Lise Piquilloud, Salvatore Grasso, Amal Jubran, Franco Laghi, Sheldon Magder, Antonio Pesenti, Stephen Loring, Luciano Gattinoni, Daniel Talmor, Lluis Blanch, Marcelo Amato, Lu Chen, Laurent Brochard, Jordi Mancebo
Journal: Intensive Care Medicine (2016)
Effect of <i>KRAS</i> and <i>NRAS</i> mutational status on first-line treatment with FOLFIRI plus cetuximab in patients with metastatic colorectal cancer (mCRC): New results from the CRYSTAL trial.
Authors: Fortunato Ciardiello, Heinz-Josef Lenz, Claus-Henning Kohne, Volker Heinemann, Sabine Tejpar, Regina Esser, Frank Beier, Christopher Stroh, Klaus Duecker, Eric Van Cutsem
Journal: Journal of Clinical Oncology (2014)

LBA443 Background: The phase III CRYSTAL study showed patients with unresectable KRAS exon 2, codon 12 and 13, wild-type (wt) mCRC (n = 666) to benefit from the addition of cetuximab to FOLFIRI first-line. Progression-free survival (PFS), overall survival (OS) times and response rate (RR) were significantly better in patients who received FOLFIRI plus cetuximab, compared with FOLFIRI alone. Recent retrospective analyses of studies involving EGFR-targeted monoclonal antibody therapy have suggested that patients with KRAS and NRAS mutations in other codons were unlikely to benefit from the addition of an EGFR-targeted agent. Thus, the impact of these additional KRAS and NRAS mutations on the efficacy and safety of FOLFIRI plus cetuximab treatment is under investigation in patients from the CRYSTAL study. Methods: KRAS (eight mutations on exons 3 [codons 59 and 61] and 4 [codons 117 and 146]) and NRAS (18 mutations on exons 2 [codons 12 and 13], 3 [codons 59 and 61] and 4 [codons 117 and 146]) mutation detection is ongoing using BEAMing (Beads, Emulsions, Amplification, and Magnetics) with a mutation detection cut-off of 0.1%. Tumor genomic DNA samples from 541 randomized patients with KRAS exon 2 wt disease (81% of KRAS wt patient population) and tumor material available are currently being screened. Treatment arms will be compared using two-sided log-rank tests for PFS and OS, and the Cochran–Mantel–Haenszel (CMH) test for response. Results: RAS mutation status is currently available from 192 patients (28.8% ascertainment) with further RAS assessment ongoing. Currently 63.5% of the samples are RAS wt and 36.5% are new RAS mutations. Conclusions: Updated information on the full RAS mutation dataset of up to 400 samples combined with the clinical data will be presented and implications for patient care discussed.
High-Risk Patients in the Evolving Landscape of Carotid Revascularization
Authors: Lily E. Johnston, Gilbert R. Upchurch
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal